SCHEMBL31664544

SCHEMBL31664544

CCc1cc(=O)n2nc(C)n(CC(=O)Nc3ccc(C(F)(F)F)cc3)c2n1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.43
▸ MAPT P10636 3/20 0.43
▸ LMNA P02545 3/20 0.42
▸ HSD17B10 Q99714 2/20 0.42
▸ TP53 P04637 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ FPR1 P21462 1/20 0.41
▸ FPR2 P25090 1/20 0.41
▸ AKR1B1 P15121 1/20 0.41
▸ ACKR3 P25106 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ TRPA1 O75762 1/20 0.40
▸ RXFP1 Q9HBX9 1/20 0.40
▸ RECQL P46063 1/20 0.39
▸ HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31713938 0.87 KDM4E (0.41) KDM4EMAPTLMNAHSD17B10TP53
SCHEMBL31664555 0.83 KDM4E (0.43) KDM4EMAPTLMNAHSD17B10TP53
SCHEMBL31664556 0.82 AKR1B1 (0.45) KDM4EMAPTLMNAHSD17B10TP53
SCHEMBL31713877 0.80 KDM4E (0.44) KDM4EMAPTLMNAHSD17B10TP53
SCHEMBL31653952 0.80 KDM4E (0.44) KDM4EMAPTLMNAHSD17B10TP53
SCHEMBL31713855 0.78 KDM4E (0.40) KDM4EMAPTLMNAHSD17B10TP53
SCHEMBL31664550 0.76 AKR1B1 (0.42) KDM4EMAPTHSD17B10TP53MEN1
SCHEMBL31664558 0.76 AKR1B1 (0.42) KDM4EMAPTHSD17B10TP53MEN1
SCHEMBL31664578 0.74 KDM4E (0.43) KDM4EMAPTLMNATP53FPR1
SCHEMBL25037269 0.73 KDM4E (0.43) KDM4EMAPTLMNAHSD17B10TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250236622-A1 BICYCLIC COMPOUNDS AS INHIBITORS OF WRN INCYTE CORPORATION (US) 2025-07-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250236622-A1 BICYCLIC COMPOUNDS AS INHIBITORS OF WRN WRN, BLM, RECQL KDM4E 3651/4885MAPT 4634/4885LMNA 1534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback